“Both VX-150 and VX-128 represent an innovative new approach to the treatment of pain, and we are encouraged to now have positive proof-of-concept data from two studies of VX-150 that demonstrate for ...

-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the ...

Vertex has stopped development of VX-961 after getting a look at phase 1 data. The NaV1.8 inhibitor failed to meet Vertex’s desired pharmacokinetic and tolerability profile, leading it to dump the ...

- Phase 2 data demonstrated that a once-daily triple combination of VX-121/ tezacaftor/VX-561 has potential for enhanced clinical benefit compared to TRIKAFTA ...

Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation -Global ...

Vertex Pharmaceuticals Incorporated VRTX has entered into an agreement to acquire ViaCyte, a private cellular therapy company, to accelerate the development of the VX-880 program in type I diabetes.

today announced the initiation of a global pivotal Phase 3 development program for fixed-dose combinations of VX-809 (lumacaftor) and ivacaftor in people with cystic fibrosis (CF) who have two copies ...